ExpreS2ion Biotech
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
14 December 2023 | Update on EU-Funded Nipah Virus Vaccine Project
10:00 CET | Virtual
ExpreS2ion Biotechnologies recently announced the award of a grant that amounts to EUR 8m (approx. SEK 90m) for the VICI-Disease consortium. 53% of the amount is a direct contribution to ExpreS2ion’s part of the project costs. The development project aims to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate.
CEO Bent Frandsen will dig deeper into the news in a live virtual event hosted by H.C. Andersen Capital on the Inderes platform. You can ask questions before or during the live event through the registration link here: https://www.inderes.dk/videos/expres2ion-biotechnologies-update-on-eu-funded-nipah-virus-vaccine-project
To pose questions ahead of time to be addressed at the webcast, please email ExpreS2ion at investor@expres2ionbio.com.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
| Datum | 2023-12-12, kl 10:30 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!